依达拉奉联合醒脑静治疗急性重型颅脑损伤的临床观察

目的:观察依达拉奉联合醒脑静治疗急性重型颅脑损伤的疗效。方法:选择2008年11月～2009年11月的急性重型颅脑损伤患者72例,将其随机分为2组:治疗组36例,采用依达拉奉联合醒脑静治疗;对照组36例,单用依达拉奉治疗。治疗后第14天统计2组APACHE-Ⅱ、格拉斯哥昏迷(GCS)评分,伤后3个月评价2组总体疗效。结果:治疗组GCS评分升高,APACHE-Ⅱ评分降低,与对照组比较差异均有统计学意义(P<0.05);治疗组疗效优于对照组(P<0.05)。结论:依达拉奉联合醒脑静治疗急性重型颅脑损伤,能够明显提高疗效,改善其神经功能缺损和预后。

Clinical Efficacy of Edaravone Combined with Xingnaojing in the Treatment of Acute Severe Brain Injury

OBJECTIVE：To analyze the clinical efficacy of edaravone combined with Xingnaojing in the treatment of acute severe head injury.METHODS：72 patients with acute severe brain injury were collected from Nov.2008 to Nov.2009 and randomly divided into 2 groups.Treatment group were treated with edaravone and Xingnaojing and control group received edaravone alone.14 days after treatment,APACHE-Ⅱ and GCS score were collected.The overall efficacies of 2 groups were evaluated three months after suffering from injury.RESULTS：The GCS score of treatment group was increased while APACHE-Ⅱ score was decreased,there was statistical significance in difference between 2 groups（P0.05）;the curative effect of treatment group was better than that of control group（P0.05）.CONCLUSION：Edaravone combined with Xingnaojing for acute severe brain injury can improve clinical efficiency,improve neurological damage and prognosis.